Abstract Aims The ELEVATE Registry was designed to study long-term outcomes with the
Heartmate 3 (HM3), a fully magnetically levitated centrifugal ventricular assist device, in a …

Despite improved outcomes of modern continuous‐flow left ventricular assist devices (CF‐
LVADs), device exchange is still needed for various indications. While the majority of CF …

The use of left ventricular assist devices (LVADs) as a treatment method for heart failure
patients has been steadily increasing; however, pathological studies showed presence of …

Contemporary centrifugal continuous-flow left ventricular assist devices (LVADs) incorporate
dynamic speed modulation algorithms. Hemocompatibility of these periodic unsteady pump …

Continuous‐flow left ventricular assist devices (LVADs) have gained tremendous
acceptance for the treatment of end‐stage heart failure patients. Among different versions …

Right heart failure (RHF) is a severe complication after left ventricular assist device (LVAD)
implantation. The aim of this study was to analyze the incidence, risk factors, and biomarkers …

Malpositioning of left ventricular assist devices (LVAD) is a risk factor for thrombosis, but its
identification from clinical imaging remains challenging. X-rays and CT scans were analyzed …

Abstract Introduction Ventricular assist devices (VADs) are considered an effective treatment
for patients with advanced heart failure, while complications associated with blood damage …

Thromboembolic complications remain a central issue in management of patients on
mechanical circulatory support. Despite the best practices employed in design and …

Introduction: Left ventricular assist devices (LVADs) are an established, durable, and life-
saving treatment option for patients with advanced heart failure. However, large vessel …